Quinazolin derivatives as emerging alpha-glucosidase inhibitors
Open Access
- 31 December 2018
- journal article
- Published by European Journal of Chemistry in European Journal of Chemistry
Abstract
A series of C-7 substituted-2-morpholino-N-(pyridin-2-ylmethyl)quinazolin-4-amine have been synthesized and biochemical assay was examined against α-glucosidase function inhibition activity. A structure activity and structure property relationship study was experimented to surface the new hit compound. This study led to the identification of C-7substituted quinazolines with minimum inhibitory concentrations (MICs) in the preffered micromolar range in addition with interesting physicochemical properties. Biological evaluation yielded eight analogs which rose with significant α-glucosidase inhibition potency (IC50 values < 2 μM, where reference compound (Acarbose) potency value is IC50 = 0.586 uM) and could be promising candidates for further lead optimization.Keywords
This publication has 30 references indexed in Scilit:
- Prevalence and Incidence Trends for Diagnosed Diabetes Among Adults Aged 20 to 79 Years, United States, 1980-2012JAMA, 2014
- Development of α-glucosidase inhibitors by room temperature C–C cross couplings of quinazolinonesOrganic & Biomolecular Chemistry, 2013
- Pd-catalyzed amination of 6-halo-2-cyclopropyl-3-(pyridyl-3-ylmethyl) quinazolin-4(3H)-oneTetrahedron Letters, 2012
- Bauhinia forficata Link authenticity using flavonoids profile: Relation with their biological propertiesFood Chemistry, 2012
- Leptin and Cardiovascular DiseaseJournal of the American College of Cardiology, 2008
- Synthesis of novel 4,6-disubstituted quinazoline derivatives, their anti-inflammatory and anti-cancer activity (cytotoxic) against U937 leukemia cell linesEuropean Journal of Medicinal Chemistry, 2008
- α- and β-Glucosidase inhibitors: chemical structure and biological activityTetrahedron, 2006
- Synthesis and antihyperglycemic activity of suitably functionalized 3H-quinazolin-4-ones.Bioorganic & Medicinal Chemistry, 2003
- Meglitinide Analogues in the Treatment of Type 2 Diabetes MellitusDrugs & Aging, 2000
- Thiazolidinediones in the Treatment of Insulin Resistance and Type II DiabetesDiabetes, 1996